ISG Announces 2025 ISG Paragon Awards™ ANZ Winners
SYDNEY--(BUSINESS WIRE)--May 8, 2025--
Information Services Group ( ISG ) (Nasdaq: III ), a global AI-centered technology research and advisory firm, has announced the winners of the ISG 2025 Paragon Awards™ ANZ, which recognize innovative sourcing partnerships that help enterprises leverage technology to make a significant and lasting impact on their businesses.
A total of 45 nominations were submitted for the ANZ program, which started in 2010 and is now in its fifteenth year. Winners were selected by an independent judge and announced at a gala awards dinner on Thursday, May 8, 2025, at the Grand Hyatt Melbourne.
The winners of the 2025 ANZ awards are:
Excellence: Outstanding delivery by a service provider
Winner: Genpact Australia Pty Ltd with AMP Limited
Innovation: Imagination and entrepreneurial spirit in helping organizations future-proof their businesses and better serve clients
Winner: Unisys Australia Pty Limited with NSW Department of Communities and Justice
Transformation: The successful transformation of an organization or key business function
Winner: PwC Australia with AMP Limited
Sustainability: Exceptional implementations of digital sustainability strategies and initiatives
Winner: HCL Technologies Limited with WaterNSW
AI Pacesetter: Substantial business impact through the adoption of AI
Winner: Tata Consultancy Services Limited with Foxtel Management Pty Ltd
Partnership of the Year: Partnerships that demonstrate seamless collaboration, leverage each other's strengths and adapt together to achieve shared objectives
Winner: Wipro Technologies Australia Pty Ltd with AusNet Services and Palo Alto Networks
'ISG research finds enterprises in Australia are investing in digital transformation to deliver rapid, measurable results and are turning to provider partnerships for support with AI-centric initiatives,' said Michael Gale, partner and regional leader, ISG Asia Pacific. 'Congratulations to the 2025 winners of the ISG Paragon Awards ANZ. Their commitment to delivering impactful business results is reflected in each of their winning partnerships.'
The 2025 ISG ANZ Paragon Awards celebrate the evolution of the sourcing industry through the application of new sourcing approaches, AI and digital technology. Full details are available here.
About ISG
ISG (Nasdaq: III ) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250508004313/en/
CONTACT: Press Contacts:
Will Thoretz, ISG
+1 203 517 3119
[email protected]
Julianna Sheridan, Matter Communications for ISG
+1 978 518 4520
[email protected]
KEYWORD: AUSTRALIA/OCEANIA AUSTRALIA
INDUSTRY KEYWORD: DATA MANAGEMENT APPS/APPLICATIONS TECHNOLOGY OTHER TECHNOLOGY SOFTWARE NETWORKS ARTIFICIAL INTELLIGENCE
SOURCE: Information Services Group, Inc.
Copyright Business Wire 2025.
PUB: 05/08/2025 07:00 PM/DISC: 05/08/2025 07:02 PM
http://www.businesswire.com/news/home/20250508004313/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ASX Penny Stocks: Frontier Digital Ventures And 2 Other Promising Picks
As the Australian market eases back into action after a brief hiatus, investors are keenly observing developments both locally and internationally, with trade talks and economic reports shaping the landscape. Despite being an older term, "penny stocks" continue to hold relevance for those looking to uncover growth opportunities in smaller or newer companies. With strong financial foundations, these stocks can offer attractive potential returns at lower price points, making them intriguing options for discerning investors. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.50 A$70.76M ★★★★★★ GTN (ASX:GTN) A$0.65 A$124.05M ★★★★★★ IVE Group (ASX:IGL) A$2.57 A$396.25M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$441.56M ★★★★★★ Tasmea (ASX:TEA) A$3.08 A$725.72M ★★★★★☆ Regal Partners (ASX:RPL) A$2.25 A$756.37M ★★★★★★ Accent Group (ASX:AX1) A$1.845 A$1.11B ★★★★☆☆ Lindsay Australia (ASX:LAU) A$0.71 A$225.19M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.37 A$159.91M ★★★★★★ CTI Logistics (ASX:CLX) A$1.815 A$146.19M ★★★★☆☆ Click here to see the full list of 1,003 stocks from our ASX Penny Stocks screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Frontier Digital Ventures Limited is a private equity firm focused on investing in and developing online classifieds businesses in emerging markets, with a market cap of A$99.75 million. Operations: Frontier Digital Ventures generates revenue from its online classifieds businesses across various regions, with notable contributions from Infocasas (A$19.43 million), Fincaraiz (A$14.14 million), Encuentra24 (A$11.65 million), and Avito (A$7.66 million). Market Cap: A$99.75M Frontier Digital Ventures has a market cap of A$99.75 million and focuses on online classifieds in emerging markets, generating significant revenue from businesses like Infocasas and Fincaraiz. Despite being unprofitable, it maintains a strong cash position with short-term assets exceeding liabilities, allowing for over a year of runway based on current free cash flow. The company has reduced its debt-to-equity ratio significantly over five years and holds more cash than total debt. Recent board changes include the appointment of Patrick Grove as Director, which may influence strategic direction amidst high share price volatility. Jump into the full analysis health report here for a deeper understanding of Frontier Digital Ventures. Gain insights into Frontier Digital Ventures' future direction by reviewing our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Imugene Limited is a clinical stage immuno-oncology company in Australia that develops immunotherapies aimed at activating the immune system to treat and eradicate cancerous tumors, with a market cap of A$119.47 million. Operations: Imugene generates its revenue from the research, development, and commercialisation of health technologies, with reported earnings of -A$1.84 million. Market Cap: A$119.47M Imugene Limited, with a market cap of A$119.47 million, is a clinical-stage immuno-oncology company that remains pre-revenue, generating less than US$1 million. Despite being unprofitable and not expected to reach profitability in the next three years, Imugene's short-term assets significantly exceed both its short and long-term liabilities. The company has more cash than debt but faces a limited cash runway of 3-4 months based on past free cash flow estimates. Recent developments include its addition to the S&P/ASX Emerging Companies Index and presentations at industry conferences by CEO Leslie Chong. Dive into the specifics of Imugene here with our thorough balance sheet health report. Review our growth performance report to gain insights into Imugene's future. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Kingsgate Consolidated Limited is involved in the exploration, development, and mining of gold and silver mineral properties with a market capitalization of A$560.50 million. Operations: The company's revenue is primarily generated from its Chatree segment, which reported A$210.69 million. Market Cap: A$560.5M Kingsgate Consolidated, with a market cap of A$560.50 million, demonstrates strong financial performance in the penny stock category. The company has shown impressive earnings growth of 1203% over the past year, significantly outpacing industry averages. Its debt management is robust, with operating cash flow covering 69% of its debt and EBIT covering interest payments 17.2 times over. Recent announcements include a share buyback program aimed at enhancing shareholder value as part of its capital management strategy. However, while short-term liabilities are covered by assets, long-term liabilities remain uncovered by current short-term assets. Unlock comprehensive insights into our analysis of Kingsgate Consolidated stock in this financial health report. Explore Kingsgate Consolidated's analyst forecasts in our growth report. Unlock our comprehensive list of 1,003 ASX Penny Stocks by clicking here. Seeking Other Investments? We've found 17 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:FDV ASX:IMU and ASX:KCN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Wingderm® Strengthens Presence in Asia at IMCAS Asia 2025
BEIJING, June 10, 2025 /PRNewswire/ -- From June 6 to 8, 2025, IMCAS Asia was successfully held in Bangkok, Thailand. As one of the world's leading medical aesthetic events, IMCAS Asia brought together the latest developments and trends in the Asian medical aesthetic market. Wingderm® once again showcased its innovative medical aesthetic solutions. Focusing on Asia's Growing Medical Aesthetic MarketThe Asian market includes both mature economies, such as China, Japan, and South Korea, as well as rapidly growing Southeast Asian countries. This makes the region a crucial player in the global medical aesthetic industry. IMCAS Asia is not only a platform for sharing knowledge, but also offers Wingderm® a valuable opportunity to better understand practitioner perspectives and stay aligned with market trends, supporting product upgrades and strategic expansion. Tech Meets Trust: Driving Mutual Growth through InnovationAt IMCAS Asia, Wingderm® presented a series of advanced medical aesthetic devices, including Mesoskin for non-invasive delivery, Lasermach for fast and comfortable laser hair removal, and Renuva, a device powered by 1550nm non-ablative fractional laser for skin resurfacing. Our success at the event was thanks to the support of our local distributor in Thailand. We will continue this close partnership for mutual benefit. Next Stop: TAS 2025 in Las VegasDriven by technology and innovation, Wingderm® is always looking for new ways to apply our technologies and enhance user experiences. Through industry events, we share our latest advancements and strengthen connections with industry professionals around the world. Wingderm® will be at booth 712 during TAS 2025, held from June 27 to 29 in Las Vegas. Please visit us there！ About Wingderm®Wingderm® since its establishment in 2016, with the aim of "Aesthetics&Technology, Easy to Achieve", provides leading and reliable intelligent photoelectric medical aesthetic devices, which have been exported to more than 80 countries, with over 25,000 units installed, recognized for safety and effectiveness by experts and beauty seekers. For more information, visit: View original content to download multimedia: SOURCE Wingderm Electro-optics Ltd. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
